SUPERNUS PHARMACEUTICALS, INC. (SUPN) — Current Report

Key Insights

• Supernus Pharmaceuticals has agreed to acquire the assets related to the compound NV-5138 or SPN-820 from Navitor Pharmaceuticals through an asset purchase agreement.
• The agreement includes milestone payments of up to $350 million contingent upon the achievement of specified development, regulatory and commercial milestones for the acquired compound.
• The company has the right to discontinue the development of the compound after the completion of the Phase 2b study if it determines the study was not successful.